Journal
JACC-HEART FAILURE
Volume 2, Issue 2, Pages 97-112Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2013.10.006
Keywords
epidemiology; heart failure; preserved ejection fraction; prognosis; treatment
Categories
Funding
- NHLBI NIH HHS [U10 HL110302] Funding Source: Medline
- National Institute for Health Research [NF-SI-0611-10227] Funding Source: researchfish
Ask authors/readers for more resources
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting. (C) 2014 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available